2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
71
Carcinoma, Hepatocellular
26
Prostatic Neoplasms
22
Neoplasm Metastasis
19
Neoplasms
18
Carcinoma, Non-Small-Cell Lung
16
Kidney Neoplasms
14
Osteosarcoma
9
Neuroendocrine Tumors
9
Colorectal Neoplasms
9
Carcinoma, Transitional Cell
9
Carcinoma, Medullary
9
Sarcoma
8
Urinary Bladder Neoplasms
7
Sarcoma, Ewing
7
Melanoma
7
Breast Neoplasms
7
Brain Neoplasms
7
Thyroid Neoplasms
6
Ovarian Neoplasms
6
Clear-cell metastatic renal cell carcinoma
6
Recurrence
5
Pancreatic Neoplasms
5
Lung Neoplasms
5
Carcinoma
5
Urethral Neoplasms
4
Triple Negative Breast Neoplasms
4
Multiple Myeloma
4
Liver Neoplasms
4
Thyroid Cancer, Papillary
3
Interventions
belzutifan
5
gallium Ga 68 dotatate
3
Everolimus
2
Blood Specimen Collection
2
vatalanib
1
tanespimycin
1
spartalizumab
1
palbociclib
1
lenvatinib
1
cabozantinib
1
Vorinostat
1
Sunitinib
1
Ranibizumab
1
Propranolol
1
PT2385
1
Oxygen-15
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Fluorodeoxyglucose F18
1
Exome Sequencing
1
Bevacizumab
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
cabozantinib
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled